Ludwig Heumann & Co. Gmbh

Heumann Pharma Gmbh & Co.

Synbias Pharma Ag

Other

Hexal Pharmaceuticals, Inc.

Schickaneder, Helmut

Schickaneder, Christian

Helmut Schickaneder

Kurt H Ahrens

Peter Morsdorf

Istvan Szelenyi

Heidrun Engler

Rolf Herter

Armin Buschauer

Stefan Postius

Walter Schunack

Volker Pfahlert

Michael Limmert

Christian Schickaneder

Kurt-Henning Ahrens

Ingomar Grafe

Stefan Huber

Kay Brune

Günther Bernhardt

Harald Hofmeier

Gert Baumann

Istvan Szeleny

Mathias Lubbe

Herbert Hansen

Hartmut Vergin

Kurt Wegner

Sigurd Elz

Guenther Bernhardt

Irene Kramer

Peter Mosdorf

Volker Pfanhlert

Geidrun Engler

Aggelos Nikolopoulos

Peter W Jungblut

Klaus Hoxer

Gunther Bernhardt

Kurt Henning Ahrens

The present invention relates to bendamustine derivatives and related compounds of formula (VII), (VIII) and (IX), and medical uses thereof in particular in cancer therapy. 

Bendamustine derivatives and related compounds, and medical use thereof in cancer therapy

The present invention relates to particular esters of bendamustine and related compounds, and medical uses thereof.

Esters of bendamustine and related compounds, and medical use thereof

A process for preparing pure N-[2-[[[5-[dimethylamino)-methyl-2-furanyl]methyl]thio]ethyl]-N'-methyl-2- nitro-1,1-ethyldiamine hydrochloride, designated Form 1 ranitidine hydrochloride, from ranitidine in methylene chloride with the addition of hydrochloric acid. The Form 1 ranitidine hydrochloride thus obtained is stable and therefore useful for producing commercial-scale quantities of Form 1 ranitidine hydrochloride.

Process for preparing form 1 ranitidine hydrochloride

A new imidazolyl propyl guanidine derivative corresponding to formula I ##STR1## is described, which is distinguished by a combination of particularly advantageous properties for the treatment of diseases of the heart and circulation.

Imidazolyl propyl guanidine derivative and a pharmaceutical composition

New benzimidazoles correponding to the general formula I ##STR1## are described, in which the pyridazinone ring is attached in the 5- or 6- position of the benzimidazole ring and R.sup.1 denotes a hydrogen atom or a straight chained or branched C.sub.1 to C.sub.4 alkyl group, R.sup.2 denotes a hydrogen atom, a straight chained or branched C.sub.1 to C.sub.4 alkyl group, a C.sub.1 to C.sub.4 alkoxy group, a hydroxy group, a halogen atom, an amino group or a nitro group, A denotes a hydrogen atom, a group of the formula ##STR2## wherein R.sup.3 denotes a hydrogen atom, an optionally substituted C.sub.1 to C.sub.4 alkyl group or a C.sub.1 to C.sub.4 alkoxy group and B denotes a cyano group, a benzoyl group or a phenylsulphonyl group, or A denotes a group of the formula ##STR3## in which m has the value 2 or 3 and n represents an integer from 1 to 6, and the physiologically acceptable salts thereof as well as processes for their preparation and pharmaceutical preparations. containing these compounds These compounds are new, effective, positive inotropic substances which do not act by the mechanism of phosphodiesterase inhibition.

Benzimidazoles and pharmaceutical preparations containing these compounds

The invention relates to pyrimidine-thioalkyl pyridine derivatives corresponding to the following general formula ##STR1## in which R.sub.1 to R.sub.4, independently of one another, represent hydrogen, lower alkyl, halogen, amino or hydroxy groups, R.sub.5 represents a free electron pair or a lower alkyl group, a halogen atom, m has the value 0 or 1, the pyrimidine-thioalkyl group being bonded in the 2-, 3- or 4-position of the pyridine ring, and to therapeutically compatible acid addition salts thereof. The invention also relates to a process for producing the new pyrimidine-thioalkyl pyridine derivatives and to medicaments containing these compounds.

Pyrimidine-thioalkyl pyridine derivatives, medicaments containing these

New imidazolylalkyl-guanidine derivatives are described, which by virtue of their agonistic action on histamine-H.sub.2 receptors and in part also due to their additional H.sub.1 -antagonistic receptor activity can be used in the treatment of cardiac diseases, certain forms of hypertension and diseases of arterial occlusion. These imidazolylalkyl-guanidine derivatives correspond to the general formula I: ##STR1##

Imidazolyl alkyl guanidine derivatives, processes for their preparation

A new process for the preparation of 2,6-dichlorodiphenylamine derivatives is described, which process provides the desired active compound in a high yield and with a very high degree of purity by a technically simple and realizable procedure.

Process for the preparation of 2,6-dichlorodiphenylaminoacetic acid

This invention relates to new stereochemically pure and stable adducts of Z-1-(p-.beta.-dimethylaminoethoxyphenyl)-1-(p-hydroxyphenyl)-2-phenyl-but- 1-ene and certain solvents which by virtue of their marked antioestrogenic activities may be used for the therapeutic treatment of benign breast diseases and hormone-dependent mammary tumors, in particularly by percutaneous application.

Stable solvent adducts of

A new process for the preparation of the nitroethane derivatives, ranitidine and nizatidine, is described which takes place via intermediate products and enables the said compounds to be prepared with a higher degree of purity. Another advantage is that in contrast to the known processes, it is not accompanied by the liberation of the highly toxic and malodorous compound, methylmercaptan.

Process for the preparation of nitroethene derivatives

New benzimidazoles corresponding to the general formula I ##STR1## are described, in which the pyridazinone ring is attached in the 5- or 6- position of the benzimidazole ring and R.sup.1 denotes a hydrogen atom or a straight chained or branched C.sub.1 to C.sub.4 alkyl group, R.sup.2 denotes a hydrogen atom, a straight chained or branched C.sub.1 to C.sub.4 alkyl group, a C.sub.1 to C.sub.4 alkoxy group, a hydroxy group, a halogen atom, an amino group or a nitro group, A denotes a hydrogen atom, a group of the formula ##STR2## wherein R.sup.3 denotes a hydrogen atom, an optionally substituted C.sub.1 to C.sub.4 alkyl group or a C.sub.1 to C.sub.4 alkoxy group and B denotes a cyano group, a benzoyl group or a phenylsulphonyl group, or A denotes a group of the formula ##STR3## in which m has the value of 2 or 3 and n represents an integer from 1 to 6, and the physiologically acceptable salts thereof as well as processes for their preparation and pharmaceutical preparations containing these compounds. These compounds are new, effective, positive inotropic substances which do not act by the mechanism of phosphodiesterase inhibition.

Benzimidazoles, and pharmaceutical preparations containing these

New 6-phenyldihydro-3(2H)-pyridazinones corresponding to the following general formula ##STR1## are described. These compounds are readily prepared in a form suitable for oral administration and are distinguished by a high positive inotropic action and have only a slight effect on blood pressure and cardiac frequency. A process for their preparation and pharmaceutical preparations containing these compounds are also described.

Piperazine substituted 6-phenyldihydro-3(2H)-pyridazinones, and

New guanidine carboxylic acid esters corresponding to the general formula I ##STR1## and a process for the preparation of these compounds are described. The compounds according to the invention are H.sub.2 -agonists optionally having an additional H.sub.1 -antagonistic component. They are distinguished by their improved oral activity. The use of the above-mentioned guanidine carboxylic acid esters and of pharmaceutical preparations containing these esters is also described.

Guanidine carboxylic acid esters and pharmaceutical preparations

New dihydropryidazinone derivatives corresponding to the following formula ##STR1## and a process for their preparation and pharmaceutical preparations containing these compounds are described. These compounds are effective positively inotropic substances with an improved therapeutic profile.

Dihydropyridazinone derivatives, a process for their preparation and

Growing community of inventors

Eckental, Germany

Helmut Schickaneder